Research programme: anti-cancer chimeric peptides - MetaMax Ltd.
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator MetaMax
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Russia
- 23 Nov 2012 Preclinical trials in Solid tumours in Russia (IV)